• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aradigm lands NIH grant for inhaled, liposomal products

August 15, 2017 By Sarah Faulkner

AradigmAradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin.

The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company.

The Phase II grant comes on the heels of a Phase I grant, which found that Linhaliq and Lipoquin are effective against M. avium complex and M. abscessus infection. The Phase II grant is slated to focus on combination therapies, since the treatment of mycobacterial infections conventionally includes multiple antibiotics.

For M. avium complex infection, researchers plan to assess the efficacy of Linhaliq and Lipoquin in combination with clarithromycin, ethambutol and amikacin. For M. abscessus infection, Linhaliq and Lipoquin will be combined with linezolid and imipenem.

The company reported that it will also investigate the emergence of antibiotic resistance.

“Pulmonary infections with non-tuberculous mycobacteria have become a serious growing public health problem in the U.S. and many other countries as they can result in debilitating lung disease and are costly to treat,” Luiz Bermudez, from Oregon State University, said in prepared remarks. “We have shown that lung-delivered liposomal ciprofloxacin is effective in in vitro and animal models of NTM without causing the emergence of resistant NTM. Patients with NTM at present typically have to use several antibiotics to avoid the emergence of resistance. This NIH grant is important as it enables us to compare the benefits of lung-delivered liposomal ciprofloxacin alone or in combination with other antibiotics.”

“Bronchiectasis and chronic lung infections with Pseudomonas aeruginosa and NTM are frequent co-morbidities. It is our goal to deliver a much needed new treatment for these patients with severe lung diseases,” principal investigator James Blanchard added.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Aradigm Corp.

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS